Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor
activity and safety of etrumadenant (AB928)-based combination therapy in participants with
metastatic castrate resistant prostate cancer (mCRPC).